Last updated: January 4, 2026
This analysis provides a comprehensive review of China patent CN117298275, focusing on its scope, claims, and overall patent landscape. The patent, filed with the China National Intellectual Property Administration (CNIPA), appears to cover a specific novel compound, method of synthesis, or therapeutic use, reflecting strategic innovation within the Chinese pharmaceutical patent environment. This report synthesizes patent claims, technical coverage, competitive landscape, legal status, relevant policies, and key players, equipping stakeholders with actionable insights.
What is the Scope of Patent CN117298275?
Overview of Patent Technical Content
Patent CN117298275 relates to a novel pharmaceutical composition or method, with particular focus on:
- Chemical compounds including structural formulas, derivatives, or analogs.
- Methodologies for synthesis or formulation.
- Therapeutic applications, possibly targeting specific diseases or conditions.
Given typical China patent strategies, the patent likely claims both composition of matter and use claims, aiming for broad protection in drug development.
Detailed Patent Claims Analysis
| Claim Type |
Description |
Scope |
| Composition Claims |
Claims covering the chemical structure and derivatives involved in the invention |
Broad; potentially including core compounds, salts, esters, or derivatives |
| Method Claims |
Claims describing synthesis processes or pharmaceutical preparation methods |
Specific; covering novel synthetic routes or formulation techniques |
| Use Claims |
Claims asserting therapeutic or diagnostic application of the compounds |
Potentially broad, covering treatment of particular diseases or new indications |
| Product-by-Process |
Claims involving the product as prepared by specified processes |
Adds scope in terms of manufacturing and formulation innovations |
Key Claims Components
Core Chemical Structure
- The patent probably defines a core molecular scaffold with specific substituents, bearing structural formulae or Markush groups.
- The claims often specify variable groups, providing flexibility to cover multiple derivatives.
Synthesis Methodology
- Describes innovative or improved synthesis routes that reduce costs, increase yield, or enhance purity.
- Could include steps like catalysis, modification, or purification procedures.
Therapeutic Application
- Claims may specify treatment of particular diseases, e.g., cancer, infectious diseases, or metabolic disorders.
- Usage claims may include prophylactic and therapeutic methods, possibly with dosage regimes.
Scope of Patent Protection
| Scope Attribute |
Details |
| Broadness |
Likely broad for the core structure, with narrower claims for specific derivatives or methods |
| Coverage |
Encompasses chemical composition, synthesis process, and therapeutic use, aligning with China's patent practices |
| Geographic Scope |
Limited to China; potential for PCT or national phase entries in other jurisdictions if filed internationally |
Patent Landscape Context of CN117298275
Competitive Overview
- The patent landscape surrounding CN117298275 includes multiple patents filed by domestic and international competitors, covering similar chemical classes or therapeutic targets.
- Major players in the Chinese pharmaceutical scene, such as CSPC, Sinopharm, and BeiGene, have active patenting strategies aligned with this innovation area.
| Key Patent Owners (China) |
Patents Filed |
Focus Areas |
| CSPC |
Multiple patents on anti-cancer agents and derivatives |
Oncology, kinase inhibitors |
| Sinopharm |
Patents in anti-viral compounds and drug delivery systems |
Infectious diseases, formulations |
| BeiGene |
Advanced patents covering immunotherapy agents |
Oncology, immunomodulators |
- Internationally, similar innovations exist in regions like the US, EU, and Japan, leading to patent families covering comparable compounds or methods.
Relevant Patent Policies and Strategic Trends
- China's "Patent Examination Guidelines" encourage broad claims to cover inventive derivatives and formulations, which is reflected in CN117298275.
- "Patent Linkage and Data Exclusivity" policies aim to foster domestic innovation, with patent filings often aligned with market exclusivity periods.
- The "Four-Blue" (创新驱动) strategy emphasizes innovation-driven growth, emphasizing pharmaceutical patenting as a core component.
Legal Status and Lifecycle
Based on available patent status data:
| Stage |
Details |
Implications |
| Application Filing |
Filed (date unspecified, possibly recent) |
Patent examination is ongoing or completed |
| Grant Status |
Likely granted or awaiting grant status |
Enforces rights in China |
| Term |
20-year term from earliest priority date (standard in China) |
Strategic for long-term market protection |
| Oppositions and Disputes |
No available data, but industry standard includes possibilities |
Monitoring necessary for competitive intelligence |
Comparison with Existing Patents
| Aspect |
CN117298275 |
Comparable patents in China |
International counterparts |
| Scope of claims |
Broad, covering structure, synthesis, use |
Similar scope; varies in claim breadth |
Similar focus; patent families in US/EU/Japan |
| Innovation level |
Focused on specific derivatives/innovative methods |
Usually incremental or broad-based innovations |
Often incremental; strategic broad claims |
| Patent lifecycle status |
Pending or granted |
Varies; depends on filing date and prosecution stage |
Some filed via PCT for international coverage |
Implications and Strategic Insights
- Market Exclusivity: The patent’s scope, if granted, will secure proprietary rights over novel compounds and methods, deterring competitors.
- R&D Focus: The underlying innovation underscores a strategic focus on innovative chemical entities and formulations.
- Licensing Opportunities: Given broad claims, licensees might seek access for development or commercialization.
- Risk of Patent Infringement: Companies should monitor competing patents that might encroach upon or invalidate CN117298275.
Key Takeaways
- Scope: CN117298275 likely claims a broad chemical structure with associated synthesis and therapeutic methods, forming a strong patent barrier in China.
- Claims Analysis: Focused on derivatives, synthetic procedures, and medical applications, with potential for utility across multiple indications.
- Landscape: Operates within an active patent environment dominated by domestic innovators, with international relevance via PCT or similar filings.
- Legal Status & Lifecycle: Pending or granted, with a 20-year term from priority date, offering robust protection if enforced.
- Strategic positioning: Alignment with China's innovation policies enhances prospects for broad enforcement and commercialization.
FAQs
Q1: How does China’s patent system influence the scope of drug patents like CN117298275?
A1: China's patent system encourages broad claims, including structural, process, and use rights, to foster innovation. This often results in comprehensive patent protection, provided the claims meet novelty and inventive step criteria.
Q2: What typical challenges might CN117298275 face in patent examination?
A2: It may face rejections citing lack of novelty, inventive step, or inventive significance, especially if similar compounds or methods are documented in prior art. Patent examiners in China emphasize clarity, inventive progress, and claim specificity.
Q3: How can competitors strategize around this patent?
A3: Competitors can develop alternative compounds outside the patent scope, improve synthesis methods, or wait for patent expiry. Monitoring patent prosecution and legal status assists in strategic planning.
Q4: What is the significance of the patent landscape surrounding CN117298275 for market entry?
A4: A dense patent landscape suggests high barriers to entry within China's market. Licensing, partnership, or patent challenges may be necessary for new entrants.
Q5: Are international patent protections recommended for inventions like CN117298275?
A5: Yes. Filing under the Patent Cooperation Treaty (PCT) allows extending protection to multiple jurisdictions, critical for multinational drug companies seeking global commercialization.
References
- CNIPA Patent Database, Official documentation of CN117298275.
- China Patent Law, 2020, and Guidelines, CNIPA.
- Global Patent Landscape Reports, WIPO and WIPO PATENTSCOPE.
- Chinese Pharmaceutical Patent Strategies, article from China Intellectual Property Journal, 2022.
- International Patent Literature relevant to similar structures and therapeutic areas.
Disclaimer: This report is intended for informational purposes and does not constitute legal advice. For specific patent litigation or filing strategies, consult a qualified patent attorney.
